ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences [Yahoo! Finance]
ANI Pharmaceuticals, Inc. (ANIP)
Last ani pharmaceuticals, inc. earnings: 2/27 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
anipharmaceuticals.com/investors_corporate_profile.php
Company Research
Source: Yahoo! Finance
Adds two commercial assets ILUVIEN ® and YUTIQ ® with significant growth potential, expanding ANI's foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafter Expected to generate additional million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies; additional EBITDA contribution expected from accelerated growth of Purified Cortrophin ® Gel in ophthalmology Increased geographic diversification with Alimera's established ex-US footprint, including direct operations in Europe PRINCETON, N.J. and ATLANTA, June 24, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) and Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”) today announced they have signed a definitive agreement pursuant to which ANI will acquire Alimera for $5.50 per share in cash at
Show less
Read more
Impact Snapshot
Event Time:
ANIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIP alerts
High impacting ANI Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ANIP
News
- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) had its price target raised by analysts at HC Wainwright from $87.00 to $94.00. They now have a "buy" rating on the stock.MarketBeat
- Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- Exclusive: Route raises $40 million Series C at a $1.4 billion valuation [Fortune]Fortune
- ANI Pharmaceuticals' CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals’ CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award WinnerGlobeNewswire
ANIP
Earnings
- 5/10/24 - Beat
ANIP
Sec Filings
- 6/24/24 - Form 4
- 6/24/24 - Form 8-K
- 6/21/24 - Form 144
- ANIP's page on the SEC website